IRIS PubliCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.166
NA - Nord America 3.082
AS - Asia 1.007
SA - Sud America 25
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 8.296
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.048
DE - Germania 1.196
IT - Italia 744
SE - Svezia 586
CN - Cina 498
PL - Polonia 429
FR - Francia 401
UA - Ucraina 325
SG - Singapore 239
IE - Irlanda 140
GB - Regno Unito 129
IN - India 93
FI - Finlandia 86
ID - Indonesia 81
RU - Federazione Russa 46
TR - Turchia 46
CA - Canada 27
BE - Belgio 26
BR - Brasile 19
IR - Iran 18
NL - Olanda 16
HK - Hong Kong 14
JP - Giappone 8
EU - Europa 6
CZ - Repubblica Ceca 5
MX - Messico 5
CH - Svizzera 4
DK - Danimarca 4
AT - Austria 3
ES - Italia 3
LT - Lituania 3
RO - Romania 3
AR - Argentina 2
AU - Australia 2
BG - Bulgaria 2
EC - Ecuador 2
EG - Egitto 2
GR - Grecia 2
KE - Kenya 2
KR - Corea 2
MC - Monaco 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
MM - Myanmar 1
NG - Nigeria 1
PE - Perù 1
PK - Pakistan 1
UG - Uganda 1
VN - Vietnam 1
Totale 8.296
Salva come PNG Salva come JPEG
Città #
Chandler 653
Kraków 426
Ashburn 272
Jacksonville 247
Singapore 187
Rome 158
San Mateo 156
Dublin 138
New York 138
Nanjing 135
Ann Arbor 122
Milan 113
Dearborn 85
Nürnberg 83
Jakarta 81
Wilmington 76
Houston 74
Lawrence 71
Cattolica 66
Woodbridge 62
Nanchang 57
Lancaster 53
Redmond 50
Boston 48
Izmir 45
Redwood City 42
Shenyang 34
Seattle 32
Moscow 28
Boardman 26
Brussels 26
Verona 26
Bremen 25
Kunming 25
Los Angeles 24
Changsha 23
Mountain View 23
Fairfield 22
Hebei 22
Munich 21
Norwalk 21
Falls Church 20
Ottawa 18
Shanghai 18
Beijing 17
Leawood 17
University Park 17
Marseille 15
Tianjin 14
Augusta 13
Hangzhou 13
Hong Kong 13
Jinan 13
Fremont 12
Guangzhou 12
Pune 11
Washington 10
Simi Valley 9
Turin 9
Bologna 8
Helsinki 8
Princeton 8
Zhengzhou 8
Cambridge 7
Changchun 7
Jiaxing 7
Toronto 7
Busto Arsizio 6
Chicago 6
Detroit 6
Edinburgh 6
Kish 6
London 6
Andover 5
Brescia 5
Hefei 5
Modena 5
Naples 5
Bari 4
Costa Mesa 4
Padova 4
Paris 4
Philadelphia 4
Sacramento 4
Santa Clara 4
Ardabil 3
Auburn Hills 3
Berlin 3
Frankfurt am Main 3
Fuzhou 3
Genoa 3
Gustavo Adolfo Madero 3
Indiana 3
Latina 3
Omsk 3
Phoenixville 3
São Paulo 3
Vaiano 3
Aci Catena 2
Amsterdam 2
Totale 4.459
Salva come PNG Salva come JPEG
Nome #
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 572
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 225
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 176
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 176
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 170
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 165
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 160
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 152
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 151
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 140
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 140
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 135
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 133
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 129
Variability of raltegravir plasma levels in the clinical setting 126
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 123
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 120
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 120
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 116
Initial antifungal strategy does not correlate with mortality in patients with candidemia 110
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 109
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 109
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 109
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 109
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 108
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 108
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 107
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 106
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 106
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 105
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 105
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 103
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 102
Cognitive reserve and neuropsychological functioning in older HIV-infected people 102
Effect of aging and human immunodeficiency virus infection on cognitive abilities 100
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 100
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 100
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 100
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 98
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 98
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 97
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 97
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 96
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 95
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 95
Immune response to influenza A(H1N1)v in HIV-infected patients 94
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 93
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 92
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 92
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 92
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 91
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 89
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 89
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 89
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 84
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 83
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 82
Lipid-lowering effect of tenofovir in HIV-infected patients 80
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 79
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 78
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 78
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 77
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 76
Immune response to influenza A(H1N1)v in HIV-infected patients 75
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 74
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 72
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 72
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 66
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 65
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 62
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 61
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 60
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 55
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 54
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 52
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 46
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 44
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 37
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 37
Totale 8.373
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.020
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.020
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020500 0 0 0 0 0 103 49 44 69 61 93 81
2020/2021696 41 86 7 74 85 37 76 16 115 22 121 16
2021/2022806 77 64 25 61 47 40 21 129 29 73 121 119
2022/20231.639 237 261 132 258 136 191 29 145 186 11 39 14
2023/20241.021 41 231 30 106 45 212 68 22 30 50 116 70
2024/2025619 55 55 120 103 222 64 0 0 0 0 0 0
Totale 8.373